Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000982
UniProt IDP62495
Primary gene name(s)ETF1
Synonym gene name(s)ERF1, RF1, SUP45L1
Protein nameEukaryotic peptide chain release factor subunit 1
Protein functionDirects the termination of nascent peptide synthesis, translation in response to the termination codons UAA, UAG and UGA. Component of the transient SURF complex which recruits UPF1 to stalled ribosomes in the context of nonsense-mediated decay, NMD of mRNAs containing premature stop codons. {ECO:0000269|PubMed:7990965}.
Subcellular locationCytoplasm.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P62495
Gene Ontology
(Biological Process)
Complete annatation
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [GO:0000184];
protein methylation [GO:0006479];
regulation of translational termination [GO:0006449];
translational termination [GO:0006415]
Gene Ontology
(Molecular Function)
Complete annatation
poly(A RNA binding [GO:0044822];
ribosome binding [GO:0043022];
RNA binding [GO:0003723];
translation release factor activity [GO:0003747];
translation release factor activity, codon specific [GO:0016149];
translation termination factor activity [GO:0008079]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829]
Protein-protein interaction108408
Phylogenetic treeP62495
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD32.201046938691881.17952314582226e-102.02480328631356e-09
AZA vs. DISU-0.04318197982172410.8645012783503410.991133096247651
AZA vs. IL70.3501830304173950.06876674305189590.744812296177348
AZA vs. SAHA0.1825264832943190.4549144336806130.795842068156414
DISU vs. CD3-2.256770954566832.81743028907044e-095.04993390932793e-08
DISU vs. IL70.3846905572886610.1275713426351150.46748054501651
DISU vs. SAHA0.2263778290437820.4392911985831460.784863089819289
DMSO vs. AZA-0.07083505441536350.6726309390937561
DMSO vs. CD3-2.283369440645398.91087204024643e-121.67175949298023e-10
DMSO vs. DISU-0.02959455965031890.9035126710724850.988283279918411
DMSO vs. IL70.42835171045580.01737011957229970.273049585560395
DMSO vs. SAHA0.2459342493849050.2975548073070080.649920072597669
HIV vs. Mock in Activation-0.1287261541223420.8358489507975520.999983755607037
HIV vs. Mock in Latency-0.08940958297571570.5882528606593370.999834320637052
IL7 vs. CD3-1.842007497100442.62512772630785e-083.62681486880277e-07
SAHA vs. CD3-2.043925302869552.43269822064462e-082.97643528589396e-07
SAHA vs. IL7-0.1714555949197390.4815355316917270.713853981954757
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -1.037584262
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.275796 0.0356583
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.013 0.923 0.963 0.915 0.905
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
-6.68 <0.0001 0.3 0.8898 -0.53 0.01 Protein Synthesis at 4; 8; and 20 hip
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1DT9 X-ray 2.7Å A=1-437.
2HST NMR - A=140-275.
2KTU NMR - A=276-437.
2KTV NMR - A=276-437.
2LGT NMR - A=1-142.
2LLX NMR - A=1-142.
2MQ6 NMR - A=1-142.
2MQ9 NMR - A=1-142.
3E1Y X-ray 3.8Å A/B/C/D=1-437.
3J5Y EM 9.7Å A=7-420.
3JAG EM 3.6Å ii=6-421.
3JAH EM 3.4Å ii=6-421.
3JAI EM 3.6Å ii=6-421.
4D5N EM 9.0Å A=5-437.
4D61 EM 9.0Å h=5-437.
5A8L EM 3.8Å Q=7-437.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Gag-Pol modulated by 20418372
Pr55(Gag) modulated by 20418372
HIV-1 virus replication enhanced by expression of human gene 18187620

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03015 mRNA surveillance pathway - Homo sapiens (human)